Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

• Status: Completed
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated nationally at 14.7%. Genotype 4 (and subtype 4a in particular) dominates the HCV epidemic in Egypt. For decades the antiviral therapy of chronic HCV infection was based on the administration of Interferon(IFN), initially alone and then in combination with Ribavirin (RBV), but this regimen was effective in only 50% of patients with genotype 1, with significant side effects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons; Ledipasvir; Ledipasvir, sofosbuvir drug combination; Peginterferon alfa-2a; Ribavirin; Simeprevir; Sofosbuvir

Criteria

Inclusion Criteria:

• • HCV infection

• Adult patients, 18years and older.

Exclusion Criteria:

• • Child score > 12

• Severe Renal impairment

• Pregnant and lactating women

• HCC or other malignant neoplasms

• Co-infection with human immunodeficiency virus (HIV)

• Co-infection with hepatitis B virus (HBV)